WO1999002142A3 - Novel composition comprising an ssri and a beta-blocker - Google Patents

Novel composition comprising an ssri and a beta-blocker Download PDF

Info

Publication number
WO1999002142A3
WO1999002142A3 PCT/EP1998/004971 EP9804971W WO9902142A3 WO 1999002142 A3 WO1999002142 A3 WO 1999002142A3 EP 9804971 W EP9804971 W EP 9804971W WO 9902142 A3 WO9902142 A3 WO 9902142A3
Authority
WO
WIPO (PCT)
Prior art keywords
ssri
blocker
beta
novel composition
release form
Prior art date
Application number
PCT/EP1998/004971
Other languages
French (fr)
Other versions
WO1999002142A2 (en
Inventor
Paul John Cummings
Ian Frederic Tulloch
Original Assignee
Smithkline Beecham Plc
Paul John Cummings
Ian Frederic Tulloch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL13386998A priority Critical patent/IL133869A0/en
Priority to PL98338017A priority patent/PL338017A1/en
Priority to JP50818599A priority patent/JP2002508003A/en
Priority to EP98946294A priority patent/EP0996466A2/en
Application filed by Smithkline Beecham Plc, Paul John Cummings, Ian Frederic Tulloch filed Critical Smithkline Beecham Plc
Priority to CA002295822A priority patent/CA2295822A1/en
Priority to EA200000112A priority patent/EA200000112A1/en
Priority to KR1020007000202A priority patent/KR20010021644A/en
Priority to BR9810996-0A priority patent/BR9810996A/en
Priority to SK7-2000A priority patent/SK72000A3/en
Priority to AU93401/98A priority patent/AU9340198A/en
Priority to APAP/P/1999/001728A priority patent/AP2000001728A0/en
Publication of WO1999002142A2 publication Critical patent/WO1999002142A2/en
Publication of WO1999002142A3 publication Critical patent/WO1999002142A3/en
Priority to NO20000107A priority patent/NO20000107D0/en
Priority to BG104119A priority patent/BG104119A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Abstract

A pharmaceutical composition comprising an SSRI in quick-release form and a β-blocker in sustained-release form.
PCT/EP1998/004971 1997-07-11 1998-07-07 Novel composition comprising an ssri and a beta-blocker WO1999002142A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EA200000112A EA200000112A1 (en) 1997-07-11 1998-07-07 NEW COMPOSITION
JP50818599A JP2002508003A (en) 1997-07-11 1998-07-07 Novel composition
EP98946294A EP0996466A2 (en) 1997-07-11 1998-07-07 Novel composition comprising an ssri and a beta-blocker
BR9810996-0A BR9810996A (en) 1997-07-11 1998-07-07 Pharmaceutical composition
CA002295822A CA2295822A1 (en) 1997-07-11 1998-07-07 Novel composition
PL98338017A PL338017A1 (en) 1997-07-11 1998-07-07 Novel composition
KR1020007000202A KR20010021644A (en) 1997-07-11 1998-07-07 Novel Comosition
IL13386998A IL133869A0 (en) 1997-07-11 1998-07-07 Novel composition novel formulations comprising an ssri in combination with a beta blocker
SK7-2000A SK72000A3 (en) 1997-07-11 1998-07-07 Novel composition comprising an ssri and a beta-blocker
AU93401/98A AU9340198A (en) 1997-07-11 1998-07-07 Novel composition
APAP/P/1999/001728A AP2000001728A0 (en) 1997-07-11 1998-07-07 Novel composition.
NO20000107A NO20000107D0 (en) 1997-07-11 2000-01-10 New mixture
BG104119A BG104119A (en) 1997-07-11 2000-02-01 A new composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9714675.7A GB9714675D0 (en) 1997-07-11 1997-07-11 Novel composition
GB9714675.7 1997-07-11

Publications (2)

Publication Number Publication Date
WO1999002142A2 WO1999002142A2 (en) 1999-01-21
WO1999002142A3 true WO1999002142A3 (en) 1999-04-15

Family

ID=10815744

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/004971 WO1999002142A2 (en) 1997-07-11 1998-07-07 Novel composition comprising an ssri and a beta-blocker

Country Status (26)

Country Link
EP (1) EP0996466A2 (en)
JP (1) JP2002508003A (en)
KR (1) KR20010021644A (en)
CN (1) CN1262627A (en)
AP (1) AP2000001728A0 (en)
AR (1) AR016128A1 (en)
AU (1) AU9340198A (en)
BG (1) BG104119A (en)
BR (1) BR9810996A (en)
CA (1) CA2295822A1 (en)
CO (1) CO4950552A1 (en)
DZ (1) DZ2556A1 (en)
EA (1) EA200000112A1 (en)
GB (1) GB9714675D0 (en)
HU (1) HUP0003074A3 (en)
ID (1) ID24191A (en)
IL (1) IL133869A0 (en)
MA (1) MA24604A1 (en)
NO (1) NO20000107D0 (en)
OA (1) OA11276A (en)
PE (1) PE99699A1 (en)
PL (1) PL338017A1 (en)
SK (1) SK72000A3 (en)
TR (1) TR200000074T2 (en)
WO (1) WO1999002142A2 (en)
ZA (1) ZA986138B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8951555B1 (en) 2000-10-30 2015-02-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8975273B2 (en) 1999-10-29 2015-03-10 Purdue Pharma L.P. Controlled release hydrocodone formulations

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1121111B1 (en) 1998-10-15 2010-02-10 Imperial Innovations Limited Compounds for the treatment of weight loss
WO2000025752A1 (en) 1998-11-02 2000-05-11 Church, Marla, J. Multiparticulate modified release composition
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
EP1793818A2 (en) * 2004-09-17 2007-06-13 Neurocure Ltd. Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder
CN100469356C (en) * 2006-09-08 2009-03-18 山东益康药业有限公司 Slowly released tablet of compound atenolol, and preparation method

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE857122A (en) * 1976-07-27 1978-01-25 Sandoz Sa NEW PHARMACEUTICAL COMPOSITION ALLOWING A CONTROLLED RELEASE OF THE ACTIVE SUBSTANCE
EP0687472A2 (en) * 1994-06-16 1995-12-20 Eli Lilly And Company Potentiation of drug response by a serotonin 1A receptor antagonist
EP0714663A2 (en) * 1994-11-28 1996-06-05 Eli Lilly And Company Potentiation of drug response by a serotonin 1A receptor antagonist
WO1997006792A1 (en) * 1995-08-16 1997-02-27 Eli Lilly And Company Potentiation of serotonin response
EP0792649A1 (en) * 1996-02-29 1997-09-03 Eli Lilly And Company Treatment of sleep disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE857122A (en) * 1976-07-27 1978-01-25 Sandoz Sa NEW PHARMACEUTICAL COMPOSITION ALLOWING A CONTROLLED RELEASE OF THE ACTIVE SUBSTANCE
EP0687472A2 (en) * 1994-06-16 1995-12-20 Eli Lilly And Company Potentiation of drug response by a serotonin 1A receptor antagonist
EP0714663A2 (en) * 1994-11-28 1996-06-05 Eli Lilly And Company Potentiation of drug response by a serotonin 1A receptor antagonist
WO1997006792A1 (en) * 1995-08-16 1997-02-27 Eli Lilly And Company Potentiation of serotonin response
EP0792649A1 (en) * 1996-02-29 1997-09-03 Eli Lilly And Company Treatment of sleep disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"PINDOLOL INDUCES A RAPID IMPROVEMENT OF DEPRESSED PATIENTS TREATED WITH SEROTONIN REUPTAKE INHIBITORS", ARCHIVES OF GENERAL PSYCHIATRY, vol. 51, no. 3, March 1994 (1994-03-01), pages 248 - 251, XP000605678 *
HJORTH S ET AL: "FURTHER EVIDENCE FOR THE INPORTANCE OF 5-HT1A AUTORECEPTORS IN THE ACTION OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 260, 1994, pages 251 - 255, XP000605645 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9320717B2 (en) 1999-10-29 2016-04-26 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8975273B2 (en) 1999-10-29 2015-03-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9278074B2 (en) 1999-10-29 2016-03-08 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9056107B1 (en) 1999-10-29 2015-06-16 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9289391B2 (en) 2000-10-30 2016-03-22 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9205056B2 (en) 2000-10-30 2015-12-08 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9198863B2 (en) 2000-10-30 2015-12-01 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9023401B1 (en) 2000-10-30 2015-05-05 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9205055B2 (en) 2000-10-30 2015-12-08 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8951555B1 (en) 2000-10-30 2015-02-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9504681B2 (en) 2000-10-30 2016-11-29 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9517236B2 (en) 2000-10-30 2016-12-13 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9526724B2 (en) 2000-10-30 2016-12-27 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9572804B2 (en) 2000-10-30 2017-02-21 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9572805B2 (en) 2000-10-30 2017-02-21 Purdue Pharma L.P. Controlled release hydrocodone formulations

Also Published As

Publication number Publication date
NO20000107L (en) 2000-01-10
AP2000001728A0 (en) 2000-03-31
CO4950552A1 (en) 2000-09-01
AR016128A1 (en) 2001-06-20
EP0996466A2 (en) 2000-05-03
CA2295822A1 (en) 1999-01-21
CN1262627A (en) 2000-08-09
KR20010021644A (en) 2001-03-15
WO1999002142A2 (en) 1999-01-21
OA11276A (en) 2003-07-31
SK72000A3 (en) 2000-12-11
PL338017A1 (en) 2000-09-25
BR9810996A (en) 2000-08-08
EA200000112A1 (en) 2000-10-30
TR200000074T2 (en) 2000-05-22
MA24604A1 (en) 1999-04-01
ZA986138B (en) 2000-01-10
PE99699A1 (en) 1999-12-21
IL133869A0 (en) 2001-04-30
AU9340198A (en) 1999-02-08
DZ2556A1 (en) 2003-02-15
GB9714675D0 (en) 1997-09-17
ID24191A (en) 2000-07-13
JP2002508003A (en) 2002-03-12
HUP0003074A2 (en) 2001-01-29
HUP0003074A3 (en) 2001-12-28
NO20000107D0 (en) 2000-01-10
BG104119A (en) 2000-12-29

Similar Documents

Publication Publication Date Title
AU6873398A (en) Table construction
AU6311698A (en) Immunopotentiators
AU2630697A (en) Connection base
AU4073997A (en) 1,4-heterocyclic metallprotease inhibitors
HK1027983A1 (en) Sustained-release compositions and method for preparing same.
AU6535098A (en) Zcytor7 cytokine receptor
AU6244098A (en) Distributed game
AU6740298A (en) Pharmaceutical composition
AU5387898A (en) Pharmaceutical agents
AU6148698A (en) Tetralone derivatives as antiarrhythmic agents
AU8350498A (en) Disintegration apparatus
AUPP038697A0 (en) Improved stomach-action molluscicides
WO1999002142A3 (en) Novel composition comprising an ssri and a beta-blocker
AU9343098A (en) Pharmaceutical composition
AU5882298A (en) New analgesic composition
AU4071897A (en) Nmda (n-methyl-d-aspartate) antagonists
AU2704799A (en) Improved gaming table tracking system and method
AU4068197A (en) Brazing and preparing articles for brazing
AU8069898A (en) Computerized craft for creating jewelry and other art curios
AU7675198A (en) Sucralfate-containing composition and process for the preparation thereof
AU9335998A (en) Bagatelle table
AU1906599A (en) Pancreatic-derived factors, and uses related thereto
ZA9810472B (en) An antimalarial composition
AU4630896A (en) Football support
AU1998997A (en) Sorting table

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 133869

Country of ref document: IL

Ref document number: 98806975.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998946294

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 501257

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 93401/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 72000

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 09462391

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2295822

Country of ref document: CA

Ref document number: 2295822

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/000416

Country of ref document: MX

Ref document number: PV2000-81

Country of ref document: CZ

Ref document number: 1020007000202

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2000/00074

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 200000112

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1998946294

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-81

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007000202

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998946294

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020007000202

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2000-81

Country of ref document: CZ